Rocket Lab’s stock soared 250% in a year, but Monday’s dip raises a key question.
Few stocks in the space industry have captured investor attention quite like Rocket Lab. Shares of the small rocket and satellite company climbed from around $21 to more than $73 over the past year, a gain of nearly 250%, before slipping almost 2% in pre-market trading today. The question hanging over every investor right now is whether that kind of momentum can last, and whether the latest dip is a warning sign or simply a buying opportunity.
Why the stock slipped this tonday
Today’s decline had nothing to do with Rocket Lab directly. The pressure came after fellow space company AST SpaceMobile saw its BlueBird 7 satellite enter an incorrect orbit before eventually de-orbiting, sending AST SpaceMobile’s stock down more than 12% in pre-market trading and pulling other names in the sector along with it.
The two companies operate in very different corners of the space industry: Rocket Lab builds and launches small orbital rockets and satellite solutions through its Electron vehicle and upcoming Neutron launch vehicle, while AST SpaceMobile focuses on building a space-based cellular broadband network that connects directly to standard mobile phones. Their businesses are distinct, but investor sentiment across the space sector tends to move together when something goes wrong anywhere in the industry.
Why the underlying growth story is hard to dismiss
Despite today’s softness, the fundamental picture at Rocket Lab is genuinely strong. The company posted record revenue of $602 million in 2025, up 38% from the prior year, with its backlog surging 73% to nearly $1.9 billion. It completed 21 missions last year with a 100% success rate, a track record that helped secure an $816 million contract from the Space Development Agency. Its space systems segment, which covers satellites and other spacecraft, has grown to roughly 67% of total revenue, reflecting how far Rocket Lab has evolved beyond being a pure launch company.
The game-changer that has not launched yet
The most anticipated chapter in the Rocket Lab story is also the most uncertain. The company’s upcoming Neutron rocket is designed to compete directly with SpaceX’s workhorse Falcon 9, reportedly at a price point roughly $15 million lower per launch. If Neutron delivers on that promise, it could open a far larger addressable market than the Electron rocket alone can reach and meaningfully shift the competitive balance in medium-lift rockets.
That is a significant conditional, however. Space flight is inherently unpredictable, and any further delays or reliability setbacks with Neutron could put serious pressure on the company’s outlook and its $1.9 billion backlog.
3 risks every investor needs to weigh carefully
Before treating Rocket Lab as a permanent portfolio fixture, three realities deserve careful consideration. First, the company is still operating at a loss, having reported a deficit of nearly $200 million against its $602 million in 2025 revenue, even as margins are beginning to improve in the right direction.
Second, shares are trading at roughly 66 times sales, a premium valuation that tells you a great deal of future success has already been priced in by the market. Third, that $1.9 billion backlog represents potential revenue, not guaranteed revenue, and converting it depends on continued flawless execution at every level of the organization.
The bigger picture for patient investors
For those willing to take a longer view, the argument for Rocket Lab still has real substance. SpaceX, its most formidable competitor, is pursuing an initial public offering at a reported valuation of roughly $2 trillion. With a market capitalization of approximately $40 billion, Rocket Lab has considerable room to grow into its valuation if Neutron succeeds and the path to profitability continues.
Whether that potential justifies the current price tag is a judgment call every investor has to make based on their own appetite for risk. This article is not financial advice, and anyone considering a position in RKLB should consult a qualified financial professional before making any decisions.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. The author and publication are not registered investment advisors and do not provide personalized investment recommendations.